Johnson & Johnson Beats Estimates as Drug Sales Offset MedTech Slump

The company’s pharmaceutical unit served as the primary engine for growth, posting a 7% increase in second-quarter sales to reach $25.31 billion. This momentum allowed J&J to lift its annual sales forecast to $101.1 billion. A standout performer was the autoimmune drug Tremfya, which surged 72.5% in sales, providing a vital buffer as the market anticipates the eventual decline of the company's long-standing blockbuster, Stelara.

Conversely, the medical device segment faced a tangible cooling period. Demand for Impella heart pumps in the U.S. fell by 2%, a stark reversal from the 14% growth recorded just three months prior. This decline follows a U.K. study that cast doubt on the efficacy of these pumps during specific high-risk coronary procedures. Despite the turbulence, CFO Joseph Wolk maintains an optimistic outlook, pointing to upcoming data releases as the catalyst to restore growth in the device sector by next year.